Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Common Equity (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Common Equity for 6 consecutive years, with $44.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 41.41% year-over-year to $44.7 million, compared with a TTM value of $44.7 million through Sep 2025, down 41.41%, and an annual FY2024 reading of $68.2 million, down 22.29% over the prior year.
  • Common Equity was $44.7 million for Q3 2025 at Ovid Therapeutics, down from $55.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $221.1 million in Q1 2021 and bottomed at $44.7 million in Q3 2025.
  • Average Common Equity over 5 years is $120.4 million, with a median of $110.7 million recorded in 2023.
  • The sharpest move saw Common Equity soared 578.12% in 2021, then tumbled 41.41% in 2025.
  • Year by year, Common Equity stood at $179.7 million in 2021, then fell by 26.41% to $132.3 million in 2022, then plummeted by 33.62% to $87.8 million in 2023, then fell by 22.29% to $68.2 million in 2024, then plummeted by 34.49% to $44.7 million in 2025.
  • Business Quant data shows Common Equity for OVID at $44.7 million in Q3 2025, $55.8 million in Q2 2025, and $59.3 million in Q1 2025.